Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs
10.1038/s41586-019-1668-3 · doi-reference
Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response
10.1158/1078-0432.ccr-21-2092 · doi-reference
Gastrointestinal stromal tumors in the setting of multiple tumor syndromes
10.1097/cco.0000000000000089 · doi-reference
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study
10.1200/jco.21.00217 · doi-reference
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
10.1200/jco.22.00294 · doi-reference
An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors
10.3389/fonc.2022.927587 · doi-reference
Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib
10.1016/j.annonc.2023.04.006 · doi-reference
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
10.1016/s1470-2045(20)30269-2 · doi-reference
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour
10.1016/j.ejca.2021.07.010 · doi-reference
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
10.1016/s1470-2045(20)30168-6 · doi-reference
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
10.1016/s0140-6736(12)61857-1 · doi-reference
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
10.1016/s0140-6736(06)69446-4 · doi-reference
10.1200/jco.2008.17.4284
10.1200/jco.2008.17.4284 · doi-reference
Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor
10.3389/fonc.2021.672500 · doi-reference
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial
10.1001/jama.2012.347 · doi-reference
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors
10.1001/jamaoncol.2020.2091 · doi-reference
Adjuvant therapy in primary GIST: state-of-the-art
10.1093/annonc/mds198 · doi-reference
Syndromic gastrointestinal stromal tumors
10.1186/s13053-016-0055-4 · doi-reference
Surgical Management of Germline Gastrointestinal Stromal Tumor
10.1245/s10434-023-13519-y · doi-reference
Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity
10.1158/1078-0432.ccr-21-1221 · doi-reference
Precision Oncology in Gastrointestinal Stromal Tumors
10.3390/curroncol30050351 · doi-reference
Relevant Trials Update in Sarcomas and Gastrointestinal Stromal Tumors: What Surgeons Should Know
10.1016/j.soc.2022.03.002 · doi-reference
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib
10.1002/cncr.28669 · doi-reference
Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade
10.1158/1078-0432.ccr-20-1706 · doi-reference
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
10.1016/j.annonc.2022.05.519 · doi-reference
Selumetinib in Children with Inoperable Plexiform Neurofibromas
10.1056/nejmoa1912735 · doi-reference
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
10.1056/nejmoa1714448 · doi-reference
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
10.1016/s1470-2045(19)30691-6 · doi-reference
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
10.1136/jitc-2021-002990 · doi-reference
Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution
10.1186/s40425-019-0689-7 · doi-reference
Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma
10.1002/cncr.32515 · doi-reference
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
10.1182/blood-2017-04-779405 · doi-reference
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma
10.1200/jco.19.02492 · doi-reference
Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous Tumor
10.1159/000486623 · doi-reference
Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor
10.1002/cncr.26098 · doi-reference
Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib
10.1097/cad.0000000000000994 · doi-reference
Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib
10.1093/annonc/mdw405 · doi-reference
10.1016/s1470-2045(16)30392-8
10.1016/s1470-2045(16)30392-8 · doi-reference
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
10.1056/nejmoa1704795 · doi-reference
Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE
10.1016/j.ejca.2021.07.016 · doi-reference
